Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 25/01/2021

    Protein anchors as a newly discovered key molecule in cancer spread and epilepsy

    Certain anchor proteins inhibit a key metabolic driver that plays an important role in cancer and developmental brain disorders. Scientists from the German Cancer Research Center (DKFZ) and the University of Innsbruck, together with a Europe-wide research network, discovered this molecular mechanism, which could open up new opportunities for personalized therapies for cancer and neuronal diseases. They published their results in the journal Cell.

    https:////www.gesundheitsindustrie-bw.de:443/en/article/press-release/protein-anchors-newly-discovered-key-molecule-cancer-spread-and-epilepsy
  • Article - 14/01/2021 Sven-Diederichs_Teaser.jpg

    Newly discovered RNA as growth driver in liver cancer

    Non-coding RNA (ncRNAs) molecules that do not encode proteins have many different functions, and some are associated with certain diseases. Prof. Dr. Sven Diederichs from the German Consortium for Translational Cancer Research and the German Cancer Research Center in Heidelberg has been conducting research into these molecules at the Freiburg University Medical Centre and discovered a ncRNA that regulates cell proliferation in cancer cells.

    https:////www.gesundheitsindustrie-bw.de:443/en/article/news/newly-discovered-rna-growth-driver-liver-cancer
  • Press release - 09/12/2020

    Combatting cancer with biological circuits

    The Freiburg engineer and biologist Prof. Dr. Barbara Di Ventura receives a Consolidator Grant from the European Research Council (ERC), one of the most prestigious prizes for European researchers, for her project "InCanTeSiMo - Intelligent cancer therapy with synthetic biology methods". Di Ventura will use the 2 Million Euros to develop a novel cancer treatment based on molecular methods from synthetic biology.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/combatting-cancer-biological-circuits
  • Press release - 03/12/2020

    HepaRegeniX achieves further milestone related to proof of safety and efficacy for MKK4 inhibition in an advanced chronic liver disease model

    New preclinical data indicate beneficial therapeutic effects in non-alcoholic steatohepatitis (NASH)-associated liver carcinomas.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/heparegenix-erreicht-meilenstein-mit-dem-nachweis-von-sicherheit-und-wirksamkeit-der-mkk4-inhibition-im-model-fuer-fortgeschritt
  • New method for analysing blood samples - 26/11/2020 Bildschirmfoto_2020-10-30_um_11.46.25.png

    Personalised therapy monitoring for malignant melanomas

    Immunotherapy has greatly improved the survival chances of patients with malignant melanoma. A study has now begun at the Department of Dermatology at the University Hospital of Tübingen to develop a way to monitor the course of treatment as effectively as possible. It involves personalised monitoring using liquid biopsies in addition to conventional PET/CT examinations. This analysis procedure of blood samples could enable closer monitoring of…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/personalised-therapy-monitoring-malignant-melanomas
  • Press release - 17/11/2020

    The Long Road to Dementia

    The chain reaction which leads to toxic protein deposits in Alzheimer’s disease starts even earlier than assumed. Researchers from Tübingen show how this process could be stopped early on.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/long-road-dementia
  • Lab-on-a-chip - 11/11/2020 Bild_3.jpg

    Microfluidic platform for the best possible cancer therapy

    Every tumour and every patient is different, and there are individual reactions to drugs as well as the problem of resistance. Patient-specific cancer treatments require innovative and cost-effective approaches. The TheraMe! consortium has developed a novel instrument: a combination of microfluidic experiments and mathematical modelling for use in cancer precision medicine to prevent incorrect therapy options.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/microfluidic-platform-best-possible-cancer-therapy
  • Press release - 09/11/2020

    Infection diagnostics 3.0: Faster thanks to nanopore sequencing

    To ensure that sepsis patients receive appropriate antibiotics as quickly as possible, Fraunhofer IGB researchers have developed a diagnostic procedure that uses high-throughput sequencing of blood samples and delivers results much faster than conventional culture-based techniques. Thanks to the latest single-molecule sequencing techniques, this process has now been further improved so that pathogens can be identified after just a few hours.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/infection-diagnostics-30-faster-thanks-nanopore-sequencing
  • Press release - 04/11/2020

    Which treatment is best for childhood brain tumors? Global trial receives funding of EUR 2.2m

    The German Childhood Cancer Foundation is providing EUR 2.2m to fund the phase III clinical trial to investigate the treatment options for certain types of childhood brain cancer with a chronic course. Initiated by the Hopp Children’s Cancer Center Heidelberg, the trial will compare two standard chemotherapy treatments and a targeted therapy to establish which is the most effective and well tolerated as a standard therapy for young patients.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/welche-behandlung-ist-die-beste-bei-hirntumoren-im-kindesalter-weltweite-studie-wird-mit-22-mio-euro-gefoerdert
  • Press release - 02/11/2020

    Juvenile myelomonocytic leukemia: International classification model allows for customized treatment

    Juvenile myelomonocytic leukemia (JMML) is a rare blood cancer of early childhood. Previous research activities have shown that JMML patients can be divided into three groups based on certain genetic markers, DNA methylation. Depending on the subgroup, statements can be made about the course of the disease.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/juvenile-myelomonocytic-leukemia-international-classification-model-allows-customized-treatment
  • Press release - 26/10/2020

    How to prevent the spread of tumor cells via the lymph vessels

    What role do the lymphatic vessels play in the metastasis of cancer cells? Scientists from the German Cancer Research Center and the Mannheim Medical Faculty of the University of Heidelberg developed a method to investigate this question in mice. The aim of the work was to identify new ways to block the dangerous colonization and spread of tumor cells.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/how-prevent-spread-tumor-cells-lymph-vessels
  • Press release - 20/10/2020

    EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment

    The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses. RNA viruses cause diseases such as influenza, SARS and COVID-19.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/eib-backs-atriva-therapeutics-eur24-million-development-potential-covid-19-treatment
  • Press release - 15/10/2020

    Pancreatic cancer: Subtypes with different aggressiveness discovered

    Tumors of the pancreas are particularly feared. They are usually discovered late and mortality is high. Until now, no targeted and personalized therapies exist. Scientists at the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine* (HI-STEM) have now succeeded for the first time in defining two differently aggressive molecular subtypes of pancreatic carcinoma.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/pancreatic-cancer-subtypes-different-aggressiveness-discovered
  • Press release - 15/10/2020

    Common Vulnerabilities of Coronaviruses

    International study in which Freiburg scientists are participating maps molecular targets for possible therapy for MERS, SARS-CoV1, and SARS-CoV2.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/common-vulnerabilities-coronaviruses
  • Intestinal peptide heals lung - 14/10/2020 Die Immuntherapie (ICI)  aktiviert Effektor-T-Zellen  und reduziert auf der anderen Seite regulatorische T-zellen, um den Tumor zu besiegen (schwarze Zellen). Die durch die Immuntherapie ausgelöste Lungenentzündung wird mit Steroidtherapie (Cortison) oder mit inhaliertem VIP (vasoaktives intestinales Peptid) behandelt. Unter VIP kommt es zur Dämpfung der Entzündung.

    Inhalation of intestinal hormone VIP helps against immunotherapy-induced pneumonia

    If cancer patients develop pneumonitis, an inflammation of the lungs resulting from immunotherapy, their symptoms and restrictions in lung function can often only be alleviated with cortisone. Researchers led by Prof. Dr. Joachim Müller-Quernheim and Dr. Björn Frye from the Freiburg University Medical Centre have been able to cure a patient's pneumonitis by inhalation of a long-known neuropeptide.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/inhalation-intestinal-hormone-vip-helps-against-immunotherapy-induced-pneumonia
  • Press release - 08/10/2020

    New class of highly effective inhibitors protects against neurodegeneration

    Heidelberg neurobiologists decode central mechanism of degenerative processes in the brains of mouse models and develop new principle for therapeutic agents.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/new-class-highly-effective-inhibitors-protects-against-neurodegeneration
  • Organ failure due to fatty liver - 24/09/2020 AdobeStock_9729015_SciePro_Leber_Mensch.jpg

    HepaRegeniX develops an active substance for liver regeneration

    When the liver stops regenerating on its own, it might be possible in future for doctors to intervene with a chemical agent. Tübingen-based HepaRegeniX GmbH is developing a promising candidate with the aim of improving the treatment of both acute and chronic liver failure.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/heparegenix-develops-active-substance-liver-regeneration
  • Phytopharmaceuticals - 14/09/2020 Cannabisnet_Bild_11.jpg

    Medicinal cannabis to be grown in Germany

    Anyone who thinks hemp is just an inconspicuous plant, whose ingredients can be used, at best, as an intoxicant, can quickly be proven wrong. Besides being used as a valuable raw material for textiles and building materials, the plant has great potential as a medicinal drug. The CANNABIS-NET network, coordinated by the University of Hohenheim, has been set up to establish the basis for producing medicinal hemp in Germany.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/medicinal-cannabis-be-grown-germany
  • Innovative Therapies - 20/08/2020 Das Bild zeigt eine pipettierende Frau in Nahaufnahme. Symbolbild für analytische Dienstleistungen des portraitierten Unternehmens.

    Labor Dr. Merk is fully committed to viral therapies

    Labor Dr. Merk & Kollegen is reorienting its business towards viral therapeutics. With this change of strategy, the company, which has decades of expertise in virology, wants to position itself in a timely fashion in the growing new market for advanced therapy medicinal products (ATMP). In gene and virotherapies (oncolytic viruses), tumour vaccines and CAR-T cell therapies, viruses are essential as vectors, killers of tumour cells or…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/labor-dr-merk-fully-committed-viral-therapies
  • Press release - 11/08/2020

    Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loan

    Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the closing of a € 8.6 million ($ 10.2 million) convertible loan led by Meneldor B.V. and High-Tech Gründerfonds (HTGF), and joined by existing shareholders and new German and international investors.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-announces-closing-eur-86-million-102-million-oversubscribed-convertible-loan
  • TGU Varimol - 24/07/2020 Das Bild zeigt zwei kleine braune Chemikalienfläschchen, die alle nötigen Reagenzien für ihre Anwendung für Kunden der Varimol enthalten.

    Click chemistry for new medical procedures

    Using a simple molecular click process, biochemists have been able to connect ring-shaped molecules with each other and couple therapeutically active substances to these molecules. Drugs can thus be specifically delivered to diseased cells and used for imaging processes or biosensors. The Stuttgart-based start-up Varimol is using this new technology to provide its customers with tailored applications that are as simple to use as a kit.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/click-chemistry-new-medical-procedures
  • Stem cell therapy for regenerating intervertebral discs - 16/07/2020 800_Wisi_Focus_Web.jpg

    Ulm’s simulator has Europe’s back

    Back pain is often caused by intervertebral disc disorders. Much has already been tried and is available to help patients. Despite extensive progress, there is still no surefire recipe for success. iPSpine, an EU-funded project to which researchers from Ulm are contributing interdisciplinary engineering and biomedical expertise, aims to design a novel therapy for back pain based on intervertebral disc regeneration.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/Ulms-simulator-has-europes-back
  • Review article (new edition) - 08/07/2020 Arm in den mithilfe einer Spritze eine Impfung gespritzt wird.

    Immunology – at the forefront of medical progress

    Immunology is constantly changing with the emergence of new technologies and areas of application, and has branched out in many directions. Immunological approaches are central to everything – be it the development of innovative active substances and vaccinations against cancer, the search for new therapies against neurodegenerative diseases or autoimmune diseases, or combatting well-known infectious diseases or new virus epidemics.

    https:////www.gesundheitsindustrie-bw.de/en/article/dossier/immunology-forefront-medical-progress
  • Press release - 15/06/2020

    German Federal Government invests 300 Million Euros in CureVac

    The German Federal Minister for Economic Affairs and Energy, Peter Altmaier, and Dietmar Hopp, SAP co-founder and co-founder of the investment company dievini Hopp BioTech holding GmbH & Co. KG, announced today that the Federal Republic of Germany will invest 300 million Euros in the biopharmaceutical company CureVac AG, a pioneer in the preclinical and clinical development of mRNA-based drugs.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/german-federal-government-invests-300-million-euros-curevac
  • Innovations in the field of endoscopy - 08/06/2020 Computeranimation der Kamerapille im Dünndarm.

    Gastroscopies with pill cameras

    A pill camera to examine the gastrointestinal tract that can be swallowed without major difficulty, controlled intuitively from the outside and deliver images in real time - why would any doctor or patient say no? To non-experts, it sounds more like science fiction but such a device is actually already in development: since 2019, Tübingen-based Ovesco Endoscopy AG and three partners have been working together on this in a project called nuEndo.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/magenspiegelung-kamerapille

Page 1 / 27

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 27
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • sb_theme_biopro.domain.mdr-ivdr
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2021
Website address: https://www.gesundheitsindustrie-bw.de/en/search